Pharmacogenetically driven patient selection for a first-in-human phase I trial of batracylin in patients with advanced solid tumors and lymphomas

PURPOSE: Batracylin (daniquidone), an ATP-insensitive topoisomerase I/II inhibitor, demonstrated wide interspecies variation in preclinical models consistent with formation of a toxic metabolite, N-acetyl-batracylin, following metabolism by N-acetyl-transferase 2 (NAT2). To minimize exposure to this...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer Chemother Pharmacol
Hlavní autoři: Kummar, Shivaani, Gutierrez, Martin E., Anderson, Lawrence W., Klecker, Raymond W., Chen, Alice, Murgo, Anthony J., Doroshow, James H., Collins, Jerry M.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2013
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7534863/
https://ncbi.nlm.nih.gov/pubmed/23912694
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-013-2244-4
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky